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Photocrosslinked Bioreducible Polymeric Nanoparticles  
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Clinical translation of polymer-based nanocarriers for systemic delivery of 
RNA has been limited due to poor colloidal stability in the blood stream and 
intracellular delivery of the RNA to the cytosol. To address these limitations, 
this study reports a new strategy incorporating photocrosslinking of bioreduc-
ible nanoparticles for improved stability extracellularly and rapid release of 
RNA intracellularly. In this design, the polymeric nanocarriers contain ester 
bonds for hydrolytic degradation and disulfide bonds for environmentally 
triggered small interfering RNA (siRNA) release in the cytosol. These photo-
crosslinked bioreducible nanoparticles (XbNPs) have a shielded surface 
charge, reduced adsorption of serum proteins, and enable superior siRNA-
mediated knockdown in both glioma and melanoma cells in high-serum con-
ditions compared to non-crosslinked formulations. Mechanistically, XbNPs 
promote cellular uptake and the presence of secondary and tertiary amines 
enables efficient endosomal escape. Following systemic administration, 
XbNPs facilitate targeting of cancer cells and tissue-mediated siRNA delivery 
beyond the liver, unlike conventional nanoparticle-based delivery. These 
attributes of XbNPs facilitate robust siRNA-mediated knockdown in vivo in 
melanoma tumors colonized in the lungs following systemic administration. 
Thus, biodegradable polymeric nanoparticles, via photocrosslinking, demon-
strate extended colloidal stability and efficient delivery of RNA therapeutics 
under physiological conditions, and thereby potentially advance systemic 
delivery technologies for nucleic acid-based therapeutics.
DOI: 10.1002/adfm.202009768
1. Introduction
Delivery of exogenous nucleic acids to 
precisely modulate gene expression in 
specific cells is recognized to have tre-
mendous potential in the treatment of a 
wide-range of human diseases.[1] One such 
technology is RNA interference (RNAi) 
using small interfering RNA (siRNA) 
with the ability to cause sequence-specific 
gene silencing of almost any sequence in 
the genome upon introduction into a cell. 
Despite this potential, clinical applications 
of this technology have been limited due 
to inefficient siRNA delivery across biolog-
ical barriers.[2] Delivery technologies using 
chemically modified siRNA molecules 
and viral vectors have yet to overcome 
several limitations, including immuno-
genicity, limited payload capacity, diffi-
culty of scaled-up vector production, and 
inefficient silencing.[3,4] In contrast, non-
viral nanoparticle-based siRNA delivery 
formulations have the potential to resolve 
these major issues as they are generally 
less immunogenic and easier to manufac-
ture, and enable greater siRNA loading.[5,6] 
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Recently, the first RNAi technology received regulatory approval 
using a lipid nanoparticle-based formulation for siRNA delivery 
for the treatment of polyneuropathies induced by hereditary 
transthyretin amyloidosis.[7,8] This landmark approval will 
undoubtedly pave the way for future RNAi nanomedicines and 
has introduced a new paradigm for genetic medicine.
Nanocarriers for cytosolic delivery of siRNA therapeutics 
must overcome several challenges for successful knockdown, 
including efficient cargo encapsulation, cellular uptake by tar-
geted cells, endosomal escape, and timely cytosolic release. In 
addition, the bioavailability of many nanoparticle systems is 
often limited to the liver following systemic administration; 
thus, there is a need for nanomaterials that can enable tissue-
mediated extrahepatic delivery as well as for nanomaterials that 
are biodegradable and nontoxic.[9]
Cationic polymers have shown promise as vectors for nucleic 
acid delivery given their ability to spontaneously self-assemble 
with anionic siRNA into condensed nanoparticles with effi-
cient payload encapsulation. Poly(β-amino ester)s (PBAE)s are 
one class of biodegradable cationic polymers being explored 
for nucleic acid delivery including for plasmid DNA, and with 
polymer structural modifications for siRNA.[10–13] This is due 
to multiple characteristics including their reversible charge, 
which promotes binding of RNA therapeutics as well as high 
buffering capacity for endosomal escape, and their degrada-
bility by hydrolysis into nontoxic byproducts under aqueous 
conditions.[14,15] Despite the promising characteristics of PBAEs 
and cationic nanoparticles in general, positive surface charge 
when injected often leads to low transfection efficacy following 
systemic administration due to nonspecific interactions with 
serum proteins and nanoparticle aggregation, resulting in poor 
colloidal stability and clearance by the mononuclear phago-
cyte system.[16,17] To reduce nonspecific protein interactions, 
one promising strategy is charge-shielding of the nanoparticle 
surface via either coatings[18] or decationization.[19] In addition, 
lower surface charge generally decreases the risk of toxicity.[20] 
The most explored surface modification for charge shielding 
of nanoparticles is the introduction of poly(ethylene glycol) 
(PEG) groups via adsorption or conjugation; however, while 
improving colloidal stability, PEGylation may also impede cel-
lular uptake and endosomal escape, thus decreasing the overall 
efficacy of the formulation.[21] In addition to charge-shielding, 
crosslinking is another strategy to improve colloidal stability 
through covalent stabilization of nanostructures, which other-
wise rely on electrostatic interactions, to form robust functional 
nanomaterials.[22] Photopolymerization for crosslinking to form 
macroscopic biomaterials has already been proven to allow 
ease of tuning material properties and scalable fabrication.[23,24] 
Thus, photocrosslinking is a promising strategy for improving 
the functionality of nanoscale biomaterials as delivery vehicles.
In this study, we report the engineering of photocrosslinked 
bioreducible nanoparticles (XbNPs) based on PBAE for nucleic 
acid-based therapeutics. Addition of a photocrosslinking 
polymer to PBAE structures yielded fully bioreducible parti-
cles with neutral surface charge, decreased nonspecific protein 
binding, and improved colloidal stability. Although UV-initiated 
polymerization has previously been demonstrated as a strategy 
to incorporate acrylate-containing molecules with added func-
tionality for nanoscale delivery systems,[25–28] this is, to our 
knowledge, the first reported photocrosslinked polymeric nano-
particle platform using a PBAE carrier. Importantly, PBAE-
based bioreducible nanoparticles show promise as RNA delivery 
vectors from a safety perspective, as their bioreducible structure 
enables environmentally triggered degradation in the reducing 
environment of the cytosol.[29] Herein, we show that this XbNP 
platform has the potential to address a variety of challenges 
facing nanoparticle gene delivery, as the XbNPs demonstrate 
improved stability in serum, improved cellular uptake, and 
tissue-mediated delivery to extrahepatic tissues compared to 
their non-crosslinked counterparts. We used XbNPs to knock 
down a reporter gene in various patient-derived cancer cell 
lines and in murine glioblastoma and melanoma cell lines, as 
well as in a metastatic melanoma model following systemic 
administration in vivo.
2. Results and Discussion
2.1. Synthesis, Design, and Nanoparticle Characteristics
2.1.1. Synthesis of Bioreducible Polymers and Photocrosslinking  
of Polymeric Nanoparticles
We used self-assembly to form well-defined nanoparticles.[30,31] 
The amine-terminated cationic polymer PBAE electrostati-
cally binds anionic siRNA and spontaneously forms nanoscale 
particles under mildly acidic aqueous conditions (pH = 5.0). 
In addition to a cationic polymer for siRNA binding, we also 
added an acrylate-terminated PBAE as the crosslinking polymer 
(Figure 1a). After self-assembly into nanoparticles, we added a 
radical photoinitiator (Irgacure 2959; Irg) and applied UV light 
to form crosslinks between the acrylate groups. Both the amine-
terminated polymer and the acrylate-terminated polymer for 
crosslinking contain disulfide bonds in their backbone struc-
tures to enable cytosolic glutathione (GSH)-triggered siRNA 
release. We synthesized the acrylate-terminated crosslinking 
polymer R64-Ac and the cationic endcap polymers R646/R647 
using one- or two-step Michael addition reactions, respec-
tively (Figure  1b). We used gel permeation chromatography 
(GPC) to measure the polymer molecular weights and to verify 
crosslinking (Figure 1c). The molecular weight after nanoparticle 
crosslinking was 42.1% and 27.7% (by Mn and Mw, respectively) 
greater than that of the non-crosslinked formulation. This 
increase in molecular weight corresponds to formation of cova-
lent bonds between the acrylate-terminated crosslinking poly-
mers (R64-Ac); and the observed increase is expected, given 
that the these R64-Ac crosslinking polymers make up 25% of 
the initial polymer population. In the absence of the photoini-
tiator, there is no difference in polymer molecular weight with 
or without UV exposure, indicating a lack of crosslink forma-
tion. The short UV exposure time of 1 min is sufficient to form 
crosslinks and does not cause any measurable degradation of 
the polymeric nanocarrier. This is a major advantage when 
using photocrosslinking compared to other crosslinking strate-
gies, since it proceeds quickly under mild reaction conditions.
We also carried out 1H NMR to assess the degree to which 
acrylate groups were crosslinked. The acrylate peaks were 
integrated and normalized to peaks corresponding to protons 
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in the backbone of the polymer structure for both crosslinked 
and non-crosslinked nanoparticle formulations (Figure S1, Sup-
porting Information). The peak intensity of the acrylate peaks 
decreased 79.1% ± 0.3%, indicating that most of the acrylate 
groups formed crosslinks. It is possible that not all acrylate 
groups formed crosslinks due to a lack of other acrylate groups 
in close proximity with which to react; however, the radical 
photocrosslinking efficiency seen in the XbNP system is com-
parable to that seen in similar photopolymerization reactions 
by other groups.[27] Due to the efficient crosslinking reaction of 
acrylate groups, the density of covalent crosslinks in the par-
ticle can easily be adjusted by altering the ratio between the 
crosslinking and the amine-terminated polymer. Moreover, to 
reduce the risk that the added covalent crosslinked network 
would impede timely intracellular release, we incorporated 
disulfide bonds into the backbone of both the acrylate- and 
amine-terminated polymers to facilitate triggered cytosolic 
release. Cargo release can easily be modulated through incor-
poration of bioreducible groups and by using PBAE struc-
tures with altered hydrophilicity to tune the rate of hydrolytic 
degradation. The ease of PBAE synthesis is also beneficial for 
forming polymer structures with diverse chemical properties, 
which has allowed high-throughput testing of combinatorial 
libraries of polymers to identify PBAEs structures for efficient 
transfection of various cell types.[32,33] Further, modulations of 
the PBAE nanocarriers can also be made for cell-type speci-
ficity of nucleic acid therapeutics.[34] These nanoparticle designs 
have demonstrated the ability to efficiently deliver genes in 
vivo after local administration.[35,36] However, these previous 
formulations have had limited success for systemic adminis-
tration mainly due to insufficient stability in the presence of 
anionic serum proteins that readily dissociate the formulation 
prior to reaching the targeted site.[37] Thus, our XbNP plat-
form could potentially improve extracellular colloidal stability 
by the addition of covalent bonds, thus improving their likeli-
hood of therapeutic success when administrated systemically. 
This crosslinked design can also be applied to other cationic 
polymeric nanoparticles that are formed by self-assembly prin-
ciples to improve their functionality and stability under physi-
ological conditions to facilitate systemic delivery of nucleic acid 
therapeutics.
2.1.2. Physical Nanoparticle Properties: Photocrosslinking  
for Shielded Surface Charge and Reduced Protein Adsorption
We used dynamic light scattering (DLS), nanoparticle tracking 
analysis (NTA), and transmission electron microscopy (TEM) 
to assess nanoparticle size and surface charge. We observed no 
differences in nanoparticle size between crosslinked and non-
crosslinked particles; their size was 204 ± 11 nm and 207 ± 12 nm, 
respectively, measured by DLS at the 60 × 10−9 m siRNA 
dose and 900 weight ratio polymer to siRNA (w/w) in PBS 
(Figure  2a). Nor did incubation in 10–50% serum influence 
the size when compared to incubation in PBS (0% serum). In 
all conditions and by all analytical techniques used, the nano-
particle size was similar both with and without crosslinking 
(Figure  2a–c). The nanoparticle size decreased slightly 
with lower siRNA dose and w/w ratios of polymer/siRNA 
(Figure S2a, Supporting Information; Figure 2f). Further, both 
the crosslinked and non-crosslinked nanoparticle formula-
tions demonstrated stability in the presence of serum (10% and 
50%) until the endpoint of 4 h (Figure  2d,e). It is promising 
that the nanoparticles remain ≈200 nm in size over time in the 
Figure 1. XbNPs for siRNA delivery. a) Schematic illustration of the electrostatic-based self-assembly into nanoparticles (NPs) and subsequent photo-
crosslinking. b) Reaction scheme of Michael addition used to form the bioreducible polymers. In the initial step, the diacrylate backbone monomer BR6 
is polymerized with the side chain monomer S4 forming the acrylate terminated crosslinking polymer R64-Ac. To form the amine-terminated polymer, 
a second synthesis step was used, in which the base polymer R64-Ac was endcapped by either monomer E6 or E7 to form R646 and R647, respectively. 
c) Molecular weight of polymeric nanocarrier assessed by GPC for crosslinked (Xlinked) and non-crosslinked (non-Xlinked) NPs with and without 
exposure to UV light. The NP formulations were formed at a polymer/siRNA ratio of 900 w/w.
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presence of serum, as particles between 70 and 200 nm exhibit 
prolonged circulation.[38]
While nanoparticle sizes were no different between the 
crosslinked and the non-crosslinked formulations, zeta poten-
tial measurements demonstrated that crosslinking reduced the 
surface charge from +22.9  ±  0.3  mV for the non-crosslinked 
nanoparticles to being neutral (–0.8 ± 1.5 mV) after crosslinking 
(Figure  2g). This shielding of the cationic charge is beneficial 
for promoting colloidal nanoparticle stability in the blood-
stream, as interactions with anionic serum proteins may lead 
to nanoparticle dissociation and loss of encapsulated siRNA 
during circulation.[1,16] Poor colloidal stability may influence 
experimental outcomes, both in vitro and in vivo, by affecting 
mechanisms such as cellular uptake and increasing overall tox-
icity,[39] and is a leading reason why cationic nanoparticles have 
not been sufficiently effective at the delivery of RNA therapeu-
tics upon systemic administration.[40] Moreover, nanoparticle 
formulations should avoid adsorption of serum opsonins to 
prevent recognition and clearance by the mononuclear phago-
cyte system.[17] Thus, nanoparticles that interact less with the 
biological environment are desirable for prolonged circulation 
to reach targeted tissues. Some cationic nanocarriers require 
surface modifications to minimize nonspecific interactions, 
with the most common approach being PEGylation of the 
nanoparticle surface for steric shielding.[41] However, the 
incorporation of PEG may reduce the degree of intracellular 
delivery of RNA therapeutics, thus these systems may require 
PEG de-shielding for successful intracellular trafficking.[21,41,42] 
Decationization is another strategy to improve the circulation 
time when using cationic polymeric nanocarriers, in which 
the polymer undergoes hydrolysis of cationic groups to form 
neutral or negatively charged nanoparticles prior to admin-
istration.[19] In this study, we have demonstrated that photo-
crosslinking can shield the surface charge that is otherwise 
positive due to the cationic polymer, eliminating the need for 
additional modifications to achieve neutral surface charge. Fur-
ther, the crosslinked nanoparticles can be tuned to be slightly 
positive or negative by adjusting the ratio between the cationic 
polymer and the RNA dose (Figure 2i). UV exposure times as 
short as 0.5  min are sufficient for loss of the cationic charge 
(Figure S2f, Supporting Information).
When incubated in serum, the non-crosslinked nano-
particles demonstrated statistically lower surface charge 
(p = 0.0039; n = 3) than the serum itself, whereas no difference 
Figure 2. Photocrosslinking reduced the nanoparticle (NP) surface charge of the otherwise cationic nanocarrier. a) NP hydrodynamic diameter assess-
ment by DLS for with (Xlinked) and without (non-Xlinked) crosslinking when incubated in PBS containing 0%, 10%, and 50% serum. b) NTA of NP 
hydrodynamic diameter. c) Representative TEM images of non-Xlinked (left) and Xlinked (right) NPs. Long-term NP stability assessed with DLS when 
incubated in d) 10% and e) 50% serum over 4 h. f) The hydrodynamic diameter of NP formulations using different polymer/siRNA ratios (w/w). g) Zeta 
potential measurements demonstrated reduced surface charge of NPs after crosslinking (*p < 0.0001; n = 3). h) Surface charge of NPs with (XL) and 
without (non-XL) crosslinking incubated in 50% serum. The zeta potential for non-XL NPs was statistically lower compared to 50% serum by itself  
(*p = 0.0039; n = 3). i) Surface charge of XbNPs formulations using different polymer/siRNA ratios (w/w). One-way ANOVA followed by Tukey’s post 
hoc test was used for statistical analyses. Error bar represents SEM.
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was observed for the XbNPs (Figure  2h). This indicates that 
there is higher adsorption of serum proteins to the non-
crosslinked nanoparticles, thus conferring anionic charge. We 
first assessed the ability of photocrosslinking to alter protein 
adsorption under high serum conditions using a bicinchoninic 
acid (BCA) assay. We compared the amount of protein adsorbed 
onto both non-crosslinked and crosslinked nanoparticles across 
two different weight ratios, 1200 and 900 w/w. The protein 
adsorption was significantly lower for the XbNPs for both the 
1200 and 900 w/w formulations (Figure 3a). This is likely due 
to the decrease in nanoparticle surface charge following photo-
crosslinking, thus reducing the ionic interactions between the 
nanoparticles and anionic serum proteins (Figure  2g). The 
decreased interactions with serum proteins may aid in XbNPs’ 
translation as a delivery technology for systemic administration, 
as the otherwise major limiting hurdle when using cationic 
polymeric nanocarriers is the competitive binding of poly-
anions that destabilize the formulation.[37]
While protein adsorption following intravenous (i.v.) injec-
tion results in a protein corona around the nanoparticle, 
which might impede intracellular delivery, adsorption of spe-
cific serum proteins may be beneficial for mediating cell- and 
tissue-specific delivery.[16,43–46] We therefore further examined 
the composition of the adsorbed proteins by running sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–
PAGE) on crosslinked and non-crosslinked nanoparticles after 
incubation in serum and in PBS as control. In the serum con-
dition, the XbNPs displayed fewer bands of lower intensity 
Figure 3. XbNPs lowered protein adsorption when incubated in serum and improved siRNA encapsulation efficiency in a high-serum condition. a) The 
protein adsorption was assessed by the BCA assay for crosslinked (Xlinked) and non-crosslinked (non-Xlinked) NPs using formulations of 1200 and 
900 w/w ratios (n = 3). *p < 0.0001, as determined by two-way ANOVA followed by Sidak’s multiple comparison. Error bars represent SEM. b) SDS–
PAGE of adsorbed proteins following incubation in serum or PBS for nanoparticles with (XL) and without (non-XL) crosslinking. Gel electrophoresis 
assessment of c) siRNA-encapsulation efficiency for crosslinked (Xlinked) and non-crosslinked (non-Xlinked) NPs using formulations of 1200, 900, 300, 
and 200 w/w ratios when incubated in 50% serum for 4 h, and d) siRNA release when incubated in cytosolic-mimicking environment of 10 × 10−3 m GSH.
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(Figure  3b), which supports the finding from the BCA assay 
that photocrosslinking lowers the overall protein adsorption. 
The most distinct band of the adsorbed proteins onto both the 
crosslinked and non-crosslinked nanoparticles was at 58  kDa, 
corresponding to albumin, which is one of the most abun-
dant proteins found in serum and has been shown to promote 
receptor-mediated nanoparticle uptake in cancer cells.[47] This 
phenomenon is due to increased albumin metabolization by 
cancer cells to support energy and amino acid consumption 
associated with rapid cancer-cell proliferation.[27,28] It is there-
fore possible that adsorption of high-molecular-weight proteins 
shields adsorbed albumin, leading to decreased cellular uptake 
of the non-crosslinked nanoparticle formulations. The results 
from the SDS–PAGE assay indicate that non-crosslinked nano-
particles adsorb greater amounts of proteins with a molecular 
weight above 58 kDa than their XbNP counterpart, suggesting 
that the crosslinked nanoparticles might promote cellular 
uptake. The specific interaction with albumin for the XbNPs is 
interesting since it potentially could be useful for biomimetic 
targeting and tumor accumulation.[48]
2.1.3. Photocrosslinking Promotes Colloidal Nanoparticle Stability
We performed siRNA gel electrophoresis assay to evaluate the 
colloidal nanoparticle stability and the encapsulation efficiency 
over time. We prepared crosslinked and non-crosslinked nano-
particle formulations with weight ratios (w/w) 1200, 900, 300, 
and 200 and incubated them in 50% serum over 4 h. The disso-
ciation of the nanoparticles, measured by release of the siRNA 
payload, was markedly lower for the crosslinked particles across 
all tested formulations both after 2 and 4 h, with the majority of 
the siRNA dose dissociated from the non-crosslinked formula-
tions at 2 h (Figure  3c). Thus, photocrosslinking of the nano-
particle formulations improves the encapsulation efficiency 
and colloidal stability of the particles under high-serum condi-
tions. The reduced surface charge and corresponding decreased 
interactions with serum proteins are advantageous as cationic 
polymeric carriers rely on electrostatic interactions to bind and 
encapsulated RNA molecules. These cationic polymer/siRNA 
nanocomplexes can easily dissociate due to competitive binding 
of cationic polymer to other anionic biomolecules.[37] Competi-
tive binding to anionic proteins in serum is a likely cause of the 
observed higher degree of nanoparticle dissociation and siRNA 
release for the non-crosslinked formulations. We also carried 
out a gel electrophoresis assay after nanoparticle incubation in 
a cytosolic-mimicking environment (10 × 10−3 m GSH)[49,50] to 
examine whether the crosslinking would affect the intracellular 
release kinetics. The high concentration of GSH in the cytosol 
readily cleaves disulfide bonds upon entry to the cytosol, leading 
to release of encapsulated molecules.[23,24,47] Across the tested 
formulations using 1200, 900, 300, and 200 w/w, we observed 
no delay in the siRNA release in the cytosolic-mimicking envi-
ronment for the crosslinked nanoparticles compared to the 
non-crosslinked nanoparticles (Figure 3d). Both the crosslinked 
and non-crosslinked particles exhibited triggered siRNA release 
in the reducing environment within 15  min. This is due to 
the presence of disulfide bonds in the structure of both of the 
polymers used for nanoparticle formation. The similar release 
kinetics between non-crosslinked and crosslinked nano-
particles indicate that crosslinking does not interfere with rapid 
intracellular release of RNA therapeutics delivered by these 
bioreducible polymeric carriers. The incorporation of stimuli-
responsive crosslinks in the nanoparticle formulations that rely 
on electrostatic interactions for improved colloidal stability in 
the blood stream and in extracellular spaces holds great promise 
for successful translation.[20,51] A strategy of high interest is the 
use of environmentally triggered crosslinks containing disulfide 
bonds, since these materials provide stability during extracel-
lular circulation while being readily cleaved in cytosol due to the 
high concentration of GSH leading to a quick release of the pay-
load.[50,52,53] In our XbNP design, both the acrylate-terminated 
and the amine-terminated polymers contained disulfide bonds 
for triggered cytosolic release while preventing nanoparticle dis-
sociation prior to being internalized into targeted cells.
2.2. In Vitro siRNA Delivery: Photocrosslinked Nanoparticles  
as a Platform for Intracellular Delivery to Cancer Cells
2.2.1. Crosslinked Nanoparticles Mediate siRNA Delivery  
in Patient-Derived Cancer Cells under High-Serum Conditions
We evaluated the siRNA delivery efficacy of the engineered 
XbNP formulations under high-serum conditions (50% serum) 
to better mimic the environment of the bloodstream after 
systemic delivery, with patient-derived glioblastoma cells 
(GBM319) as the first cancer cells tested. To modulate the 
degree of crosslinking, we varied the ratio between the acrylate 
polymer (R64Ac) and end-capped polymer (R646), and nano-
particles were formulated with and without photocrosslinking. 
For all the ratios tested, the crosslinked formulations provided 
superior siRNA-mediated GFP knockdown in the GBM319 
human brain cancer cells compared to the matched non-
crosslinked formulations with an optimized mass ratio of 1:3 
(R64Ac to R646) causing 83% ± 5% silencing of GFP expres-
sion (Figure  4a). We then explored the duration of UV expo-
sure needed for photocrosslinking, and we observed that only 
0.5 min of UV exposure was required to achieve efficient trans-
fection in high-serum conditions, with no significant difference 
measured for UV exposures between 0.5 and 2 min (Figure 4b). 
When UV exposure lasted for 3 min or longer, siRNA-mediated 
knockdown decreased significantly, likely due to degradation of 
the polymer.
We also compared nanoparticle formulations with varying 
weight ratios (w/w) between the polymer and siRNA dose, as 
were those containing amine-terminated polymers with different 
endcaps (termed R646 or R647). For all tested formulations, the 
crosslinked nanoparticles outperformed their non-crosslinked 
counterparts, and the formulations with R646 led to the greatest 
transfection of up to 96% ± 2% siRNA-mediated GFP knock-
down (Figure  4c,d; Figure S3a, Supporting Information). This 
great efficacy observed under high-serum conditions shows the 
tremendous potential of XbNPs to be used as a nanoparticle 
platform for systemic siRNA delivery. The presence of serum 
in culture media generally interferes with in vitro transfection. 
Polyethylenimine (PEI), for instance, is a commonly used 
nanocarrier with efficient transfection capability in serum-free 
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media; however, the addition of just 10% serum drasti-
cally decreases its efficacy.[54] Not only did photocrosslinking 
improve the transfection efficacy of the nanoparticles, but it 
also reduced toxicity. At the highest tested polymer concentra-
tion prepared, the 1200 w/w ratio, a 50% decrease in viability 
was observed for the R646-based non-crosslinked formulation, 
whereas the photo crosslinked formulation showed minimal tox-
icity (Figure 4e). The reason for the reduced toxicity is likely due 
to the shielded surface charge after photocrosslinking, as cati-
onic nanoparticles have been shown to exhibit increased toxicity 
compared to neutral or anionic particles.[55]
Further, we evaluated the polymer concentrations and siRNA 
doses required for high transfection efficacy in high-serum 
conditions. For the polymer, a concentration of 0.8 mg mL–1 or 
higher is required to achieve greater than 75% siRNA-mediated 
knockdown (Figure 4f). For the siRNA dose, there was no statis-
tical difference in the transfection between the doses of 20 × 10−9 
and 100 × 10−9 m, which shows that the photocrosslinked nano-
carrier provided highly potent siRNA delivery to patient-derived 
glioblastoma cells (Figure  4g) at low dose. Low toxicity was 
observed across all the tested crosslinked nanoparticle formula-
tions (Figure S3b–d, Supporting Information). We observed no 
Figure 4. XbNPs provided superior siRNA-mediated knockdown in patient-derived glioblastoma cells (GBM319) in high-serum conditions and fol-
lowing preincubation for 6 h compared to non-crosslinked nanoparticles (NPs). In vitro transfection in 50% serum of GBM319-GFP+ cells assessed by 
flow cytometry analyzing siRNA-mediated knockdown for a) crosslinked (Xlinked) and non-crosslinked (non-Xlinked) NPs formulated with different 
ratio of acrylate-terminated (Ac) and amine-endcapped (E) polymers (*p < 0.0001; two-way ANOVA followed by Sidak’s multiple comparisons) and 
b) Xlinked NPs prepared with different UV exposure times (*p  <  0.0001; one-way ANOVA). c) Representative fluorescence microscopy images of 
GBM319-GFP+ treated with XbNPs carrying either scRNA or siRNA targeting GFP (scale bars = 200 µm). d) siRNA-mediated knockdown (*p < 0.05; 
two-way ANOVA followed by Sidak’s multiple comparisons) and e) viability (*p < 0.005; two-way ANOVA followed by Sidak’s multiple comparisons) 
assessed by MTS assay for transfection in 50% serum of non-Xlinked and Xlinked NPs formulated with either R646 or R647 as the amine-terminated 
polymer using 900 or 1200 w/w formulations. siRNA-mediated knockdown of XbNPs with altered f) polymer (*p < 0.0001; one-way ANOVA followed by 
Tukey’s post hoc test) and g) siRNA (*p < 0.01; one-way ANOVA followed by Tukey’s post hoc test) concentrations. h) siRNA-mediated knockdown and 
i) viability in GBM319 when transfected with XbNPs in 50% and 100% serum. j) Transfection following preincubation at varied times in complete serum 
(*p < 0.0001; two-way ANOVA followed by Sidak’s multiple comparisons). Error bars represent SEM and n = 4.
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cellular toxicity for the photocrosslinker Irg at the transfection 
concentration of 0.17 mg mL–1 and the concentration can even 
be increased at least by a magnitude to 1.7  mg  mL–1 without 
any toxicity issues (Figure S3e, Supporting Information). Wil-
liams et al. demonstrated in their study that Irg (Irgacure 2959) 
is well tolerated by many cell types and species.[56]
2.2.2. Long-Term Colloidal Nanoparticle Stability Following  
Preincubation in Serum without Loss in Efficacy
We also evaluated the efficacy of the engineered nanoparticles 
in complete (100%) serum conditions to model systemic admin-
istration. The XbNPs demonstrated the same degree of siRNA-
mediated knockdown in patient-derived glioblastoma cells in 
complete serum as in 50% serum condition with low toxicity 
(Figure  4h,i). To examine the long-term colloidal nanoparticle 
stability in complete serum, we pre-incubated the XbNPs 
and non-crosslinked particles in 100% serum at 37  °C  for up 
to 6 h prior to transfection experiments in complete serum. 
The degree of siRNA-mediated knockdown decreased as 
pre-incubation time increased for the non-crosslinked nano-
particles, whereas knockdown with the XbNPs was unaffected: 
even after 6 h of pre-incubation in complete serum, XbNPs 
caused 82% ± 2% GFP knockdown (Figure  4j). Together, the 
long-term stability and high transfection efficacy under high-
serum conditions show the promise of the XbNP platform for 
systemic siRNA delivery.
2.2.3. Cellular Uptake and Endosomal Escape of Engineered  
Nanoparticle Formulations
To elucidate the mechanisms of the improved siRNA delivery 
efficacy for the XbNPs, we evaluated cellular uptake and 
endosomal escape in patient-derived glioblastoma cells at 
high-serum conditions. In these experiments, Cy5-siRNA 
was used, and cellular uptake was initially compared at dif-
ferent time-points post-transfection. After both 6 and 24 h 
post-treatment and in both 50% and 100% serum, the XbNPs 
were taken up by cells more efficiently than non-crosslinked 
nanoparticles (Figure 5a,b; Figure S4, Supporting Information). 
To study endosomal escape, we used confocal microscopy to 
visualize the nuclei and lysosomes, along with the Cy5-siRNA 
in the nanoparticle formulations (Figure  5c). We evaluated 
endosomal escape by quantifying the colocalization of the lys-
osomes and Cy5-nanoparticles, with lower colocalization cor-
responding to effective endosomal escape. The results showed 
no differences between the crosslinked and non-crosslinked 
nanoparticle formulations, demonstrating that the shielded 
charge following photocrosslinking does not significantly 
affect endosomal escape (Figure  5d–f). Thus, the mechanism 
through which XbNPs facilitate enhanced siRNA-mediated 
knockdown is thought to be via improved cellular uptake. The 
XbNPs with improved encapsulation of siRNA, prolonged par-
ticle stability in pure serum (Figure 3c), and reduced adsorption 
of high-molecular-weight proteins (such as immunoglobulins) 
(Figure 3b) enhance cellular uptake.
2.2.4. Nanoparticle Platform for siRNA Delivery to Various  
Glioma Cells
We evaluated XbNPs for their potential to serve as a platform 
for efficient siRNA delivery to other glioblastoma cell lines. This 
is of importance because brain tumors are heterogeneous;[57] 
hence, robust delivery to various brain cancer cells is required 
for effective treatment of glioma patients. We tested the nano-
particle formulations in GBM1A, a patient-derived glioblas-
toma cell line with high stemness.[58] Stem-like glioma cells are 
extremely evasive and resistant when it comes to radiation ther-
apies[59] and contribute greatly to disease progression.[60] Novel 
Figure 5. XbNPs enhanced cellular uptake compared to non-Xlinked NPs in patient-derived glioblastoma cells (GBM319) upon transfection in high-
serum conditions. Cellular uptake in GBM319 cells assessed by flow cytometry after a) 6 h (*p < 0.0001; n = 4) and b) 24 h (*p < 0.0001; n = 4) following 
transfection in 50% and 100% serum for crosslinked (Xlinked) and non-crosslinked (non-Xlinked) nanoparticles (NPs) carrying Cy5-labeled siRNA. 
c) Confocal microscopy images of cellular uptake for NP carrying Cy5-labeled siRNA 24 and 48 h posttreatment (scale bars = 20 µm). d) Representative 
image 24 h posttreatment with XbNPs showing nanoparticle (Cy5) and lysosome/endosome colocalization in yellow. e) Representative 2D scattergram 
24 h posttreatment with XbNPs, in which region 3 represents colocalized pixel intensities. f) NP and lysosome/endosome colocalization 24 and 48 h 
post-treatment with Xlinked and non-Xlinked NPs (n = 3). Two-way ANOVA followed by Sidak’s multiple comparisons were used for statistical analyses. 
Error bars represent SEM.
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therapeutics for glioblastoma must be able to address glioma 
cells broadly, including those with stem-like properties, in order 
to control disease progression. In GBM1A, XbNPs at 1200 w/w 
achieved >50%  siRNA-mediated GFP knockdown while still 
having low toxicity (Figure 6a,b). Over a range of siRNA dose 
from 20 × 10−9 to 120 × 10−9 m and polymer doses from 0.8 to 
1.1 mg mL−1, corresponding to 500–1200 w/w, knockdown was 
observed to be ≈10–50% (Figure  6c,d), with knockdown in 
GBM1A stem-like brain cancer cells especially sensitive to 
siRNA dose.
The XbNPs were also evaluated in GL261 cells, a commonly 
used murine glioma model. As in the GBM1A cells, the XbNP 
formulation of 1200 w/w caused >50%  GFP knockdown with 
low cytotoxicity (Figure  6e,f). Together, as observed in the 
patient-derived glioblastoma cell line GBM319, the XbNP for-
mulations also outperformed the non-crosslinked formulations 
in GBM1A and GL261 cells in terms of siRNA-mediated knock-
down. The results suggest that the XbNPs could potentially 
serve as a next-generation nanoparticle platform for siRNA-
based therapeutics for glioma. Their ability to transfect diverse 
glioma cells is crucial given the intrinsic heterogeneity of glio-
blastoma,[57] and future genetic therapeutics that address the 
heterogeneous cell population may lead to improved outcomes 
for glioma.
2.2.5. Photocrosslinked Nanoparticles for siRNA Delivery  
to Melanoma Cells
We further evaluated the XbNPs’ ability to provide siRNA-
mediated knockdown in murine melanoma cells (B16F10) in 
high-serum conditions (50% serum). The XbNPs outperformed 
their non-crosslinked counterparts in terms of both increased 
knockdown efficacy and reduced toxicity (Figure 7a–c).
A critical property of nanocarriers to enable potent sys-
temic delivery of siRNA is high and stable encapsulation of 
the siRNA therapeutics. To assess the encapsulation efficiency, 
we performed a RiboGreen RNA assay, in which we increased 
the siRNA dose while keeping polymer concentration constant 
to modulate the w/w of nanoparticle formulations. Across all 
the tested nanoparticle formulations (200–800 w/w), efficient 
siRNA encapsulation was observed (Figure 7d), with the XbNPs 
at 270 w/w showing statistically higher siRNA encapsulation 
than the non-crosslinked formulation. Higher siRNA payload 
promotes transfection efficacy, as the 400 w/w formulation 
provided almost complete siRNA-mediated GFP knockdown 
(Figure 7e).
2.2.6. Gal8-Assay Demonstrates Improved Cellular Uptake  
in Melanoma Cells for Crosslinked Nanoparticles
Critical hurdles for successful intracellular delivery of nucleic 
acid-based therapeutics involve cellular uptake and endosomal 
escape. Nanoparticle endocytosis must be followed by endo-
somal escape for successful delivery; otherwise, endosomal 
entrapment renders the nanoparticle and its cargo useless as 
it is degraded via the endo/lysosomal pathway.[61] For poly-
meric nanoparticles with titratable amine groups, endosomal 
escape occurs in part as the internalized particle buffers pH 
changes in the endocytic vesicle, ultimately leading to an 
increase in osmotic pressure and subsequent vesicle rupture 
Figure 6. XbNPs provided robust siRNA-mediated knockdown in various glioblastoma cell lines in high serum (50%) conditions. a) siRNA-mediated 
knockdown (*p <  0.01) assessed by flow cytometry and b) viability assessed by the MTS assay in GBM1A cells following treatment of crosslinked 
(Xlinked) and non-crosslinked (non-Xlinked) nanoparticles using 1200 and 900 w/w formulations. c) Transfection of GBM1A using XbNP formulations 
with varied polymer concentrations (0.8–1.1 mg mL–1) and siRNA doses (60 and 100 × 10−9 m), corresponding to 500–1200 w/w and d) dose-dependent 
(10 × 10−9–120 × 10−9 m) siRNA-mediated knockdown for XbNPs. e) siRNA-mediated knockdown (*p < 0.05) and f) viability in GL261 cells following 
treatment with XbNPs using 1200, 1050, and 900 w/w formulations. Two-way ANOVA followed by Sidak’s multiple comparison were used for statistical 
analyses. Error bars represent SEM and n = 4.
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and nanoparticle release.[62] This mechanism, termed the 
“proton sponge effect,” has been the subject of debate among 
groups studying nanoparticle-based drug and gene delivery.[62] 
Although elucidation of the exact mechanisms underlying 
endosomal escape of PBAEs is still under active investigation, 
a recently developed assay utilizing Gal8 to visualize endo-
somal disruption allows the quantitative assessment of nano-
particle endosomal escape in vitro.[63] We used this method to 
evaluate cellular uptake and endosomal disruption in B16F10 
cells, in which the XbNP and non-crosslinked formulations 
contained Cy5-siRNA and the B16F10 cells expressed a Gal8-
GFP fusion protein. In the assessment of cellular uptake 
quantifying Cy5-spots/cell, statistically higher uptake was dem-
onstrated for the XbNPs compared to non-crosslinked nano-
particles (Figure 7f). To assess endosomal escape, we quantified 
Gal8-GFP spots/cell, corresponding to the number of endo-
somal disruption events.[63] Endosomal escape was not dif-
ferent between the XbNPs and non-crosslinked nanoparticles 
(Figure  7g). Representative microscopy images from the 
Gal8-assay comparing untreated and nanoparticle-treated cells 
(Figure  7h,i) clearly demonstrate how efficient the engineered 
PBAE nanocarrier is at facilitating endosomal disruption 
for intracellular siRNA delivery to the cytoplasm. This dem-
onstrates that the mechanism for improved siRNA delivery 
Figure 7. XbNPs facilitated superior siRNA-mediated knockdown in murine melanoma cells (B16F10-GFP+) in high serum (50%) conditions compared 
to non-crosslinked nanoparticles (NPs) attributed by improved cellular uptake. a) GFP knockdown (*p < 0.0001; n = 4; two-way ANOVA followed by 
Sidak’s multiple comparisons) assessed by flow cytometry and b) viability (*p < 0.0001; n = 4; two-way ANOVA) assessed by MTS following treatment 
with crosslinked (Xlinked) and non-crosslinked (non-Xlinked) NPs using 1200 and 900 w/w formulations with altered polymer concentration. c) Rep-
resentative fluorescence microscopy images of B16F10-GFP+ treated with XbNPs carrying either scRNA or siRNA targeting GFP (scale bars = 200 µm).  
d) siRNA encapsulation efficiency for nanoparticles with various w/w formulations assessed by RiboGreen assay (*p = 0.020; n = 2; Holm−Sidak 
corrected multiple Student’s t-test). e) siRNA-mediated knockdown in B16F10 cells using 700 and 400 w/w NP formulations with altered siRNA dose 
(*p <  0.005; n = 4; two-way ANOVA followed by Sidak’s multiple comparisons). Assessment of f) cellular uptake quantified by Cy5 spots per cell 
(*p < 0.0001; n = 3; two-tailed Student’s t-test) and g) endosomal escape quantified by Gal8-GFP+ per cells in B16F10 cells using the Gal8-GFP recruit-
ment assay, in which the NPs used contained Cy5-labeled siRNA. Representative images of Gal8-GFP+ B16F10 cells h) without treatment and i) after 
treatment with NPs (scale bars = 100 µm). Error bars represent SEM.
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efficacy of the XbNPs in B16F10 cells is improved cellular 
uptake of siRNA, which is in line with the mechanistic results 
found in patient-derived glioblastoma cells. Additionally, the 
XbNP formulation contains both secondary and tertiary amines 
that undergo protonation at the lower pH of the endosomal 
compartment leading to osmotic pressure, which causes endo-
somal disruption. The results indicate that, despite the surface 
charge-shielding due to photocrosslinking, amines remain 
accessible for buffering in the XbNP formulation, thus leaving 
the desirable endosomal escape efficiency unchanged.
2.3. Photocrosslinked Nanoparticles for Systemic siRNA 
Delivery to Tumors In Vivo
2.3.1. Tissue-Mediated Nanoparticle Delivery
We evaluated the XbNPs for systemic siRNA delivery following 
i.v. injection. We initially used XbNPs containing IR-labeled 
siRNA to evaluate biodistribution after systemic administra-
tion. This study demonstrated that photocrosslinking PBAE 
nanoparticles improved targeting to the lungs (Figure  8a,b; 
Figure S5, Supporting Information). In addition, both XbNPs 
and non-crosslinked nanoparticles facilitated siRNA delivery to 
the brain to some degree. This finding is in agreement with a 
recent study showing that non-crosslinked PBAE nanoparticles 
facilitated active transport across a biomimetic in vitro assay 
of the BBB endothelium and delivery to the brain in vivo fol-
lowing systemic administration.[12] This result might be due 
in part to the adsorption of albumin shown for both XbNPs 
and non-crosslinked PBAE nanoparticles (Figure 3b). Lin et al. 
demonstrated that their albumin-based nanoparticles facilitated 
BBB crossing via mechanisms of SPARC and gp60-mediated 
transport.[64] Moreover, differences in cumulative fluorescent 
intensity observed between crosslinked and non-crosslinked 
formulations are most likely due to the nanoparticles that did 
not extravasate and accumulate in organs, but instead were 
excreted in urine and stool.
To broaden the potential of nanomedicine carrying RNA 
therapeutics, there is a need for nanocarriers capable of extra-
hepatic delivery. The recent success of the lipid nanoparticle 
formulation Onpattro that was FDA-approved in 2018 demon-
strated liver-targeted siRNA delivery for the treatment of poly-
neuropathies.[8] Based on learnings from Onpattro’s clinical 
success, key features required for clinical translation are low 
surface charge and efficient siRNA encapsulation, both of which 
are facilitated by photocrosslinking in this study. Despite early 
translational success for RNA-based therapies, the challenge 
remains to develop nanoparticle designs for delivery targeted to 
tissues beyond the liver. The Onpattro lipid nanoparticles facili-
tate adsorption of apolipoprotein E (ApoE; 34  kDa) following 
i.v. administration, leading to delivery to hepatocytes.[8] In 
contrast, our XbNPs have specific affinity to albumin (58 kDa; 
Figure  3b), which facilitates different biodistribution. A key 
factor that likely correlates with the protein adsorption is the 
nanoparticle surface charge, which can dictate tissue-targeting. 
Cheng et al. developed a lipid nanoparticle system termed selec-
tive organ targeting (SORT) in which they modulated the lipid 
composition of nanoparticles and thereby altered the surface 
charge through which they were able to achieve tissue-specific 
mRNA delivery.[65] They demonstrated lung-targeted delivery of 
their neutrally charged lipid nanoparticle formulation, which is 
consistent with the current findings. Through slight changes 
of the surface charge via tuning of the lipid composition, the 
tissue specificity of the SORT nanoparticles could be tailored. 
In a non-lipid nanocarrier system, we demonstrate for XbNPs 
that altered ratios between polymer and siRNA enabled differ-
ential tissue targeting. XbNPs using 400 w/w ratio facilitated 
preferential organ delivery to the spleen (Figure  8c,d). When 
comparing the radiant efficiency of each organ to all analyzed 
organs for each formulation, the XbNPs using 900 w/w facili-
tated statistical higher delivery to the lungs and the XbNPs 
using 400 w/w facilitated preferential delivery to the spleen 
(Figure  8e). The differential tissue targeting observed is likely 
due to difference in surface charge that can be easily tuned by 
altering the amount of polymer mixed with siRNA during the 
self-assembly step of the XbNP formulation (Figure 2i).
2.3.2. Preferential Uptake in Cancer Cells and siRNA-Mediated 
Knockdown In Vivo
Melanoma cells are highly metastatic and commonly metasta-
size to the lungs.[66] To establish an in vivo model to approxi-
mate melanoma metastasis to the lungs, we injected melanoma 
cells i.v. that expressed luciferase and tdTomato (B16F10-Luc 
= tdTomato+). IVIS imaging of the bioluminescence showed 
that the melanoma cells colonized and formed tumors in the 
lungs and grew exponentially over time (Figure S6, Supporting 
Information).
We established a similar model by creating B16F10 tumors 
expressing GFPd2 to analyze nanoparticle uptake in different 
cell types of the lungs. We administered XbNPs containing 
Cy5-siRNA i.v. and harvested the lungs after 18 h. We assessed 
nanoparticle uptake by specific cell populations by flow cytom-
etry, measuring internalization in cancer cells, epithelial cells 
(CD31+), endothelial cells (CD326+), and hematopoietic cells 
(CD45+). The nanoparticle uptake by the melanoma cells was 
statistically higher compared to all other phenotypes (Figure 8f; 
p = 0.0033; n = 5), demonstrating that the XbNPs selectively tar-
geted cancer cells over other cell types in the lungs. Preferen-
tial delivery to cancer cells has been observed for certain PBAE 
structures in previous in vitro studies. Sunshine et al. explored 
DNA delivery using a PBAE nanocarrier in a wide-range of cell 
types and showed that modulations of the small-molecular end-
caps strongly influence cell-specificity.[34] Other studies using 
PBAEs as vectors for either DNA or siRNA therapeutics have 
demonstrated preferential delivery to cancer cells over healthy 
cells as a result of modulation of the polymer structure.[11,67–69] 
These in vitro transfection studies were all performed in low-
serum conditions, allowing the intrinsic properties of PBAEs 
to facilitate preferential delivery. In the case of XbNPs, the 
decreased nonspecific interactions with serum proteins after 
administration into the bloodstream suggest that PBAEs 
can enable preferential delivery to cancer cells even after i.v. 
administration. In addition, the specific protein interaction of 
albumin with the nanoparticle surface after photocrosslinking 
may serve as another mechanism for tumor targeting, since 
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aggressive cancer cells use albumin as an essential source of 
energy during their outgrowth.[70,71] For instance, Cao et  al. 
demonstrated for their nanoparticle system that pre-decoration 
with albumin prior to administration led to tumor-targeted 
delivery in metastatic breast cancer model.[48]
In a subsequent in vivo experiment, we injected B16F10-Luc+ 
cells and allowed metastasis-like lesions to form over 7 days 
prior to treatment. We administered XbNPs carrying either 
siRNA targeting the luciferase expression, or Bcl-2 as a 
therapeutic, or scRNA (control) repeatedly via i.v. injections at 
day 7, 9, 11, and 13 after tumor inoculation. Bcl-2 is an anti-
apoptotic protein upregulated in malignant cells;[72] accordingly, 
silencing of Bcl-2 expression has been shown to induce apop-
tosis in malignant melanoma both in preclinical and clinical 
studies.[66,73,74] Thus, we utilized siRNA targeting luciferase 
(siLuc) as the bioluminescence readout gene target and Bcl-2 
(siBcl-2) as therapeutic gene target. We monitored the biolu-
minescence from the melanoma in the lungs over time, which 
Figure 8. XbNPs enabled organ delivery beyond the liver with preferential siRNA uptake in cancer cells leading to siRNA-mediated knockdown in 
tumors colonized in the lungs. a) Biodistribution of nanoparticles with (Xlinked) and without (non-Xlinked) crosslinking carrying IR-labeled siRNA 
using formulations of 900 w/w ratios after i.v. injection and b) their representative IVIS images showing the fluorescent intensity of the IR-labeled 
siRNA. *p < 0.0005; n = 5; two-way ANOVA followed by Sidak’s multiple comparison. c) Biodistribution of XbNPs using 400 w/w formulation (n = 3) 
and d) a representative IVIS image of the organ accumulation after i.v. injection. e) Radiant efficiency distribution based to the radiant efficiency in all 
of the organs for XbNPs formulations using 400 and 900 w/w. *p < 0.01; n = 3–5; two-way ANOVA followed by Sidak’s multiple comparison. f) Assess-
ment of cellular uptake in different cell types in the lungs for XbNPs carrying Cy5-labeled siRNA after i.v. injection using flow cytometry. *p = 0.0033; 
n = 5; one-way ANOVA followed by Tukey’s post hoc test. g) Bioluminescence intensity of B16F10-Luc+ cells colonized in the lungs monitored by IVIS 
imaging. XbNPs carrying siRNA targeting luciferase (siLuc) or Bcl-2 (siBcl-2), or scRNA as control were systemically administered 7, 9, 11, and 13 days 
(arrows) after tumor inoculation. *p < 0.005; n = 7; two-way ANOVA followed by Dunnett’s multiple comparisons. h) Serum levels of AST and ALT, 
biomarkers for liver health, following four repeated injections of XbNPs or no treatment. *p = 0.13 (AST), *p = 0.65 (ALT); n = 4; two-tailed Student’s 
t-test. Error bars represent SEM.
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demonstrated knockdown both for XbNPs carrying siLuc and 
siBcl-2, showing that the XbNP enabled potent systemic siRNA 
delivery to the melanoma cells (Figure 8g; p < 0.005; n = 7). The 
activity of the biomarkers aspartate aminotransferase (AST) 
and alanine transaminase (ALT) for liver health showed no 
significance difference in blood serum for animals given four 
repeated i.v. injections of XbNPs compared to control animals 
without treatment (Figure 8h). Thus, the engineered XbNPs or 
the presence of the photocrosslinker Irg does not cause meas-
urable hepatotoxicity. This is likely due to the intrinsic bio-
degradability and bioreducibility of the polymers in the XbNP 
formulation, which allow quick degradation into nontoxic 
byproducts under aqueous or reducing conditions.[20] The low 
toxicity ensures safety of the nanoparticle formulation while 
also allowing repeated administration for effective therapeutic 
treatment. If in future studies in larger animals, Irg becomes 
a concern, it can be removed using Amicon 10  kDa MWCO 
filters or similar, prior to administration. Taken together, the 
ability of the engineered XbNPs to enable systemic delivery to 
metastatic melanoma tumors could open new avenues for safe 
and effective siRNA delivery for the unmet need of treatment 
of metastatic cancers. The differential organ-targeted delivery 
could also broaden its therapeutic potential for other diseases.
3. Conclusion
We designed XbNPs to address the main issue of colloidal sta-
bility of biodegradable cationic polymeric vehicles to broaden 
their use for systemic siRNA delivery. We synthesized biore-
ducible PBAEs to serve both for crosslinking and for payload 
encapsulation, with disulfide bridges facilitating environmen-
tally triggered intracellular release. Photocrosslinking provided 
both improved colloidal nanoparticle stability, which improved 
payload encapsulation in high-serum conditions, and surface 
charge shielding, which reduced adsorption of anionic serum 
proteins. XbNPs were observed to demonstrate superior siRNA-
mediated knockdown in various glioblastoma cell lines as well 
as in melanoma cells compared to non-crosslinked formula-
tions in high-serum conditions. XbNPs are internalized readily 
by cells, which together with their enhanced stability explains 
their great efficacy in high serum. Another key aspect of intra-
cellular trafficking is endosomal escape, for which the presence 
of both secondary and tertiary amines of XbNPs leads to effi-
cient buffering at low pH, leading to endosomal disruption. 
In in vivo studies, XbNPs containing labeled siRNA targeted 
cancer cells and facilitated differential organ-targeted delivery 
through simple tuning of the polymer/siRNA ratio. In par-
ticular, formulations of XbNPs using 900 and 400 w/w formu-
lations accumulated selectively in either the lungs or spleen, 
respectively, following systemic administration. XbNPs further 
demonstrated knockdown both when carrying siRNA targeting 
a reporter gene (luciferase) and the anti-apoptotic gene Bcl-2 
after i.v. injections in a metastatic melanoma model, in which 
tumors colonized the lungs. Taken together, the improved col-
loidal stability, surface-charge shielding, high transfection effi-
cacy in high-serum conditions, efficient endosomal escape, 
environmentally triggered nanoparticle degradation and RNA 
release, and overall targeted and safe in vivo delivery capacity 
make XbNPs promising as a robust nanoparticle platform for 
systemic delivery of RNA therapeutics. The photocrosslinking 
strategy can also be applied generally to other cationic nano-
carriers for nucleic acid delivery that rely on self-assembly to 
form nanoparticles for improved stability under physiological 
conditions.
4. Experimental Section
Materials: The chemicals used in the synthesis of the base monomer 
BR6 were all purchased from Sigma-Aldrich (St. Louis, MO). The 
other monomers used in the polymer syntheses are as follows: 
4-amino-1-butanol (S4; CAS no. 13325-10-05) was purchased from 
Thermo Fisher Scientific (Carlsbad, CA), 2-(3-aminopropylamino)
ethanol (E6; CAS no. 4461-39-6) was purchased from Sigma-Aldrich, 
and 1-(3-aminopropyl)-4-methylpiperazine (E7; CAS no. 4572-031) 
was purchased from Alfa Aesar (Ward Hill, MA). The siRNA 
targeting eGFP with 5′-CAAGCUGACCCUGAAGUUCTT (sense) and 
3′-AACUUCAGGG-UCAGCUUGCC (antisense) (Ambion Silencer 
eGFP) and negative control siRNA used as the scrambled RNA 
(scRNA) with 5′-AGUACUGCUUACGAUACGGTT (sense) and 
3′-CC-GUAUCGUAAGCAGUACUTT (anti-sense) (Ambion Silencer 
negative control #1) were purchased from Thermo Fisher Scientific. The 
siRNA targeting firefly luciferase with 5′-AGAAGGAGAUCGUGGACUAUU 
(sense) and 3′-UAGUCCACGAUCUCCUUCUUU (antisense) was 
purchased from Dharmacon (Lafayette, CO). The siRNA targeting 
Bcl-2 with 5′-GCAUGCGACCUCUGUUUGATT (sense) and 
3′-UCAAACAGAGGUCGCAUGCTT (anti-sense) was purchased from 
Genepharma (Shanghai, China). Cy5-labeled siRNA (SIC005) was 
purchased from Sigma-Aldrich. Plasmid pCAG-GFPd2 was a gift from 
Connie Cepko (Addgene plasmid # 14760; http://n2t.net/addgene:14760; 
RRID:Addgene_14760).[75] PiggyBac transposase expression plasmid 
(PB200A-1) was purchased from System Biosciences (Palo Alto, CA).
Polymer Synthesis and Photocrosslinking: The bioreducible monomer 
2,2′-disulfanediylbis(ethane-2,1-diyl) diacrylate (BR6) was synthesized 
using a method similar to that reported by Kozielski et  al.[10] In brief, 
2-hydroxyethyl disulfide (10  mmol) was acrylated in dichloromethane 
(DCM) with acryloyl chloride as the acrylation reagent (300 mmol) and 
in the presence of triethylamine (TEA; 300 mmol). Following overnight 
reaction at room temperature, the TEA HCl precipitate was removed by 
filtration. The product was washed with water and dried with sodium 
sulfate, and the solvent was removed by rotary evaporation. For the 
synthesis of bioreducible PBAE, the diacrylate backbone monomer BR6 
and the side chain monomer 4-amino-1-butanol (S4) were dissolved 
in anhydrous tetrahydrofuran (THF) at a molar ratio of 1.05:1 and a 
total monomer concentration of 500  mg  mL–1. The Michael addition 
reaction was allowed to proceed for 24 h at 60  °C with stirring. For 
crosslinker preparation, the resulting acrylate-terminated base polymer 
R6-4-Ac was precipitated in anhydrous diethyl ether, washed twice 
with ether, dried under vacuum for 48 h, and dissolved in anhydrous 
DMSO at 100  mg  mL–1 at –20  °C with desiccant. For preparation of 
amine-terminated PBAEs, the acrylate-terminated-based polymer 
was end-capped with either 2-(3-aminopropylamino)ethanol (E6) or 
1-(3-aminopropyl)-4-methylpiperazine (E7). The end-capping molecules 
were dissolved in THF and added to the base polymer (0.5 m final 
concentration of end-cap and 167  mg  mL–1 of base polymer) and 
reacted for 1 h at room temperature to form polymers R6-4-6 and 
R6-4-7. As above, the end-capped polymers were purified by diethyl ether 
precipitation and two ether washes. The remaining ether was removed 
by vacuum for 48 h, and the polymers were dissolved in anhydrous 
DMSO at 100 mg mL–1 and stored as aliquots at −20 °C with desiccant.
To form the nanoparticles, the polymer and siRNA were diluted 
separately in 25 × 10−3 m of sodium acetate buffer (NaAc; pH = 5.0) at 
desired concentrations. In the polymer solution, the acrylate-terminated 
polymer (R64-Ac) as crosslinker and end-capped polymer (R646 or 
R647) were mixed together and mixed with the siRNA solution. Irgacure 
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2959 (Irg), the radical photoinitiator, was dissolved in NaAc to a final 
concentration of 1.0  mg  mL–1. The Irg solution was mixed with the 
nanoparticles at a 1:1 volume ratio, and the mixture was exposed to 
UV light (UV lamp F15T8/BL: 15 W and wavelength of 350  nm; EIKO; 
Shawnee, Canada) for specified times to obtain photocrosslinked 
nanoparticles. Irg stock solutions were stored as 100 mg mL–1 aliquots in 
DMSO at –20 °C until use.
Characterization of Polymers and Crosslinking: GPC and 1H NMR: 1H 
NMR was used to characterize the polymer structures and the degree 
of crosslinking. The polymers were dissolved in deuterated DMSO 
(DMSO-d6) and nanoparticles were first lyophilized and then dissolved 
in DMSO-d6 for characterization using a Bruker 500  MHz NMR and 
analyzed using TopSpin 3.6 software. To determine the degree of 
crosslinking, the acrylate peaks, which are used to form crosslinks upon 
exposure to UV in the presence of the photoinitiator Irg, were integrated 
and normalized to protons peaks in the PBAE backbone.
GPC was used to characterize the molecular weight of polymers 
relative to linear polystyrene standards using a refractive index 
detector (Waters, Milford, MA). To measure the molecular weight after 
crosslinking, nanoparticles were formed as described above, and then 
lyophilized to remove aqueous buffer. Prior to characterization, samples 
were dissolved in butylated hydroxytoluene-stabilized THF, filtered 
through a 0.2 µm polytetrafluoroethylene filter.
Nanoparticle Characterization of Physical Properties and Colloidal 
Stability: DLS using a Zetasizer Pro (Malvern Panalytical) was used 
to characterize the hydrodynamic diameter of the nanoparticle 
formulations. The measurements were carried out both in 1 × PBS and 
in 1 × PBS with low (10%) or high (50%) serum content. Measurements 
were carried out in PBS to characterize the influence of polymer 
concentration and siRNA dose on nanoparticle size and in the presence 
of serum to examine whether crosslinking affected particle size under 
physiological conditions. To assess the colloidal stability of the particle 
formulations when incubated in low and high serum conditions, DLS 
measurements were made for up to 4 h.
Zeta potential measurements were made with the same DLS 
instrument via electrophoretic mobility to analyze the surface charge 
of the nanoparticle formulations and to characterize the impact of 
photocrosslinking, UV exposure time, polymer concentration, and 
siRNA dose.
NTA and TEM were used to further analyze particle size. For the NTA 
experiments, nanoparticles were diluted in PBS at a 1:150 v/v ratio and 
then analyzed with a NanoSight NS300 (Malvern, Westborough, MA, 
USA) to obtain 20–100 particles per frame using the NanoSight NTA 
3.2 software. For TEM, nanoparticles were prepared, and 20 µL aliquots 
were added to carbon-coated copper TEM grids (Electron Microscopy 
Sciences, Hatfield, PA, USA), then grids were washed three times for 
10 s each with MilliQ water, and thereafter dried at room temperature for 
10 min before they were imaged.
Lastly, a gel electrophoresis assay was performed to investigate 
the stability and bioreducible nature of the crosslinked particles. The 
crosslinked and non-crosslinked nanoparticles using 1200, 900, 300, 
and 200 were compared after incubation in either 50% serum for 0, 
2, and 4 h or a reducing environment (10 × 10−3 m of GSH) for 0.25, 
0.5, and 1 h. Serum alone and siRNA alone were used as controls. 
Samples and controls containing 167 × 10−9 m siRNA except in the 
serum-only control were loaded in an 1% agarose (UltraPure Agarose, 
Invitrogen, Carlsbad, CA) gel with 0.001 mg mL−1 ethidium bromide, and 
the gel was run for 20 min at 100 V and imaged with UV light exposure.
Protein Adsorption: BCA and SDS–PAGE: For protein adsorption 
evaluation, nanoparticles were incubated with 100% serum or with PBS as 
a control in 1.5 mL tubes (LoBind, Eppendorf) for 1 h at 37 °C. The mixture 
was centrifuged at 18 000 g for 1 h at 4 °C, and the pellet was washed and 
then resuspended in PBS. The protein concentration was then measured 
using the BCA assay following the manufacturer’s instructions. For 
analysis of individual proteins, SDS–PAGE analysis was carried out using 
4–15% Mini-PROTEAN TGX Precast Protein Gels (Bio-Rad) with 1× Tris/
Glycine/SDS (Bio-Rad) as the running buffer. Gel electrophoresis was run 
at 150 V for 45 min in a Mini-PROTEAN Tetra cell (Bio-Rad).
Cell Culture and Cell Line Preparation: GBM319 patient-derived 
glioblastoma cells, GL261 murine glioma cells, and B16-F10 murine 
melanoma cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM; Thermo Fisher Scientific) supplemented with 10% fetal 
bovine serum (FBS) and 1% penicillin/streptomycin. GBM1A patient-
derived glioblastoma cells were cultured as neurospheres in DMEM-F12 
medium (Life Technologies) with 2% v/v B-27 serum-free supplement 
(Invitrogen), 1% v/v antibiotic–antimycotic, 20  ng  mL–1 epidermal 
growth factor (PeproTech, Rocky Hill, NJ, USA), and 10  ng  mL–1 basic 
fibroblast growth factor (PeproTech). For generation of reporter 
cell lines for optical readout for siRNA transfection experiments, a 
PiggyBac transposon/transposase system was used to generate cell 
lines constitutively expressing a destabilized form of GFP (GFPd2)[75] 
as described previously.[76] The PiggyBac transposon plasmid PB-CAG-
GFPd2 was constructed in a laboratory and is available on Addgene 
(Addgene plasmid #115665; http://n2t.net/addgene:115665; RRID:Ad
dgene_115665).[76] The PiggyBac transposon plasmid used to induce 
cells to express a firefly luciferase-tdTomato fusion protein (PB-fLuc 
= tdT, Addgene plasmid #120870; http://n2t.net/addgene:120870; 
RRID:Addgene_120870) was prepared from PB-GFPd2 and pcDNA3.1(+)/
Luc2 = tdT using restriction enzyme cloning. pcDNA3.1(+)/Luc2 = tdT 
was a gift from Christopher Contag (Addgene plasmid #32904; http://
n2t.net/addgene:32904; RRID:Addgene_32904).[77] PiggyBac transposase 
expression plasmid (PB200A-1) was purchased from System Biosciences 
(Palo Alto, CA). Cell lines were stably induced to express PiggyBac 
transposon expression cassettes as previously described and sorted to 
stably expressing population of cells using a Sony SH800 cytometer as 
previously described.[76]
siRNA Delivery In Vitro: Transfection and Viability: Cells were seeded 
into 96-well tissue culture plates at a density of either 5000 (B16F10), 
15  000 (GBM319 and GL261), or 20  000 (GBM1A) cells per well in 
100  µL complete medium and allowed to adhere overnight. GBM1A 
neurospheres were first dissociated into single cells and plated into wells 
coated with 5 µg mL–1 laminin (Sigma) for 3 h at 37 °C, and cells were 
allowed to adhere for 48 h. Nanoparticles were formed in 25 × 10−3 m 
NaAc. For the crosslinked formulations, photoinitiator was added and 
UV exposure applied as described above. Each nanoparticle condition 
was formulated with either siRNA targeting GFP or a scrambled control 
siRNA (scRNA). Prior to the addition of nanoparticles, the cell culture 
medium was replaced with 100  µL of complete media with specified 
serum content (10–100%). Nanoparticles were added to each well at a 
1:5 ratio of nanoparticles to medium, with a final RNA concentration of 
20 × 10−9–120 × 10−9 m per well, and allowed to incubate with cells at 
37 °C for 2 h, after which the mixture of particles and media was replaced 
with fresh complete medium. Flow cytometry was performed using a BD 
Accuri C6 flow cytometer (BD Biosciences) with HyperCyt autosampler 
to assess knockdown of GFP expression after 2 (B16F10), 4 (GL261), 
5 (GBM1A), or 7 (GBM319) days. Knockdown efficacy was quantified by 
normalizing the geometric mean fluorescence of cells treated with siRNA 
to that of cells transfected with corresponding formulation containing 
scRNA in FlowJo (n = 4).
The MTS CellTiter 96 Aqueous One (Promega, Madison, WI) cell 
proliferation assay was performed 24 h post-transfection according 
to the manufacturer’s instructions as a measure of cell viability. The 
metabolic activity of treated cells was normalized to that of untreated 
cells (n = 4).
Cellular Uptake and Endosomal Escape: Flow Cytometry, Confocal 
Microscopy, and Gal8 Assay: In the experiments for cellular uptake, 
formulations were prepared with 20% Cy5-labeled siRNA and 80% 
unlabeled siRNA. The nanoparticles were added to cells in media with 
specified serum content (50% or 100%) and allowed to incubate for 2 h, 
after which cells were washed with PBS and detached via trypsinization. 
Cells were further washed with heparin (50 µg mL–1 in PBS) to remove 
surface-bound nanoparticles and were thereafter resuspended in 
FACS buffer (2% FBS in PBS) for flow cytometry analysis to quantify 
nanoparticle uptake.
Confocal microscopy was used to visualize nanoparticle uptake 
and endosomal escape. GBM319 cells were plated on Nunc Lab-Tek 
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8-chambered borosilicate cover-glass well plates (155411; Thermo Fisher 
Scientific) at 30 000 cells per well 1 day prior to transfection in 250 µL 
media with specified serum content (50% or 100%). The nanoparticles 
were prepared as described above with 20% Cy5-labeled siRNA and 
80% unlabeled siRNA, and 50  µL was administered to each well 
and incubated with cells for 2 h. After particles and media were replaced 
with fresh complete media, and prior to imaging, cells were stained for 
30  min with Hoechst 33342 (Thermo Fisher Scientific) nuclear stain 
at a 1:5000 dilution and Cell Navigator Lysosome Staining dye (AAT 
Bioquest, Sunnyvale, CA) at a 1:2000 dilution. Cells were washed twice 
and incubated in phenol-red free media, and live-cell imaging was 
performed at 37 °C in 5% CO2. Images were acquired using a Zeiss LSM 
780 microscope with Zen Blue software and a 63× oil immersion lens. 
Specific laser channels used were 405 nm diode, 488 nm argon, 561 nm 
solid-state, and 639 nm diode lasers. Laser intensity and detector gain 
settings were maintained across all image acquisitions.
The Gal8-GFP recruitment assay was performed to assess 
endosomal disruption/endosomal escape of nanoparticles based on a 
method recently reported by Kilchrist et al.[63] Briefly, B16F10 cells were 
engineered to constitutively express a Gal8-GFP fusion protein using the 
PiggyBac transposon plasmid PB-GFP-Gal8 constructed in a laboratory 
(Addgene plasmid #127191; http://n2t.net/addgene:127191; RRID:Add
gene_127191).[78]
Nanoparticles encapsulating 20% Cy5-labeled siRNA and 80% unlabeled 
siRNA were incubated with cells for 2 h in media with 50% serum, after 
which media were replaced with fresh complete media and stained with 
Hoechst 33342 nuclear stain (1:5000 dilution). Gal8-GFP recruitment 
was analyzed using a Cellomics ArrayScan VTI with live-cell imaging 
module; cell count was generated using an algorithm to extrapolate the 
area surrounding Hoechst-stained cell nuclei, endosomal disruption was 
reported as the average number of punctate Gal8-GFP spots per cell, and 
cellular uptake reported as the average number of Cy5 spots per cell.
Animals: For the in vivo studies, 6–8 week old female C57BL/6J mice 
(Jackson Laboratory, Bar Harbor, ME, USA) were housed in standard 
facilities and were supplied with ad libitum access to food and water. 
All animal studies were performed in strict accordance with the NIH 
guidelines for the care and use of laboratory animals (NIH publication 
no. 85-23 Rev. 1985). The laboratory, investigators, and procedures were 
approved with animal protocol MO18M388 by the Animal Care and Use 
Committee (ACUC) of the Johns Hopkins University.
In Vivo Lung Metastasis Model, Nanoparticle Biodistribution, and 
Cellular Uptake: To establish metastasis-like lesions in the lungs, 
100 000 B16F10 cells suspended in 100 µL of PBS were injected i.v. into 
mice by the lateral tail vein. To allow an optical readout of the tumor 
formation, B16F10-Luc=tdTomato cells were used, and tumor growth 
was monitored via IVIS imaging. In the biodistribution study, 7 days 
after tumor inoculation, nanoparticles encapsulating siRNA labeled 
with IR fluorescent dye (IRDye800CW; Integrated DNA Technologies, 
Coralville, IA, USA) were injected i.v. (n = 3–5). A control group (n = 3) 
was not injected with nanoparticles to account for the contribution 
of autofluorescence of the organs. The animals were euthanized 18 h 
post-administration, and the organs were collected. IVIS (PerkinElmer, 
Waltham, MA, USA) imaging was used to analyze the biodistribution of 
the fluorescent nanoparticles, and the images were analyzed in Living 
Image software (PerkinElmer).
In the study of cellular uptake in the lungs, tumors were established 
as described above using B16F10 GFPd2+ cells. After 14 days, 
nanoparticles encapsulating Cy5-labeled siRNA were injected i.v. (n = 4) 
to allow analysis of cellular uptake, and untreated animals were included 
as controls (n  = 2). Mice were euthanized 18 h post-administration, 
and lungs were collected, minced, and dissociated using the Lung 
Dissociation kit (Miltenyi Biotec) according to the manufacturer’s 
instructions. Red blood cells were lysed in ACK buffer, and the remaining 
cells were incubated for 30 min at 4 °C with antibodies against epithelial 
(CD326-APC/Cy7), endothelial (CD31-BV421), and immune (CD45-BV421) 
cell markers (all antibodies from BioLegend, San Diego, CA, USA), see 
Table  1 for details. The cells were then analyzed using a CytoFlex flow 
cytometer (Beckman Coulter).
Efficacy and Safety for Systemically Administrated Nanoparticles: To 
evaluate siRNA-mediated knockdown following systemic nanoparticle 
administration, the bioluminescence signal from the B16F10 tumors 
in the lungs was monitored by IVIS. Prior to imaging, 3.75  mg 
d-luciferin (Cayman Chemical Company) in 150 µL volume was injected 
intraperitoneally (i.p.) in each mouse. Image analysis was carried out 
using Living Image software to quantify the total bioluminescence of 
the colonized tumors. The nanoparticles were loaded with either siRNA 
targeting firefly luciferase (siLuc), siRNA targeting Bcl-2 (siBcl-2), or 
negative control siRNA (scRNA), and bioluminescence was used to 
determine whether successful delivery was achieved.
Any potential hepatotoxicity of the systemically delivered 
photocrosslinked nanoparticles was examined. Animals received four 
repeated i.v. injections of nanoparticles and untreated animals were 
used as controls. Blood was collected from each animal after 8 days after 
initiation of treatment, and the serum was collected by centrifugation at 
1500 rcf for 15 min at 4 °C. The serum in treated and untreated animals 
was analyzed for AST activity and ALT (Sigma-Aldrich), key biomarkers 
for liver health. The AST and ALT activity assays were performed 
according to manufacturer’s instructions.
Statistical Analyses: All results are presented as mean ± standard 
error of the mean (SEM). All statistical analyses were performed using 
Prism software (GraphPad Prism, San Diego, CA, USA), and p  <  0.05 
was considered statistically significant. For the analysis of the physical 
nanoparticle properties, one-way ANOVA followed by Tukey’s post 
hoc test was used to compare nanoparticle size and surface charge 
of the different formulations. For the analysis of the total protein 
adsorption, two-way ANOVA followed by Sidak’s multiple comparison 
was used. For the analyses of in vitro transfection and viability, one-way 
ANOVA followed by Tukey’s post hoc test was used to compare the 
influence of UV exposure time, PBAE concentration, siRNA dose, and 
Irg concentration. Additionally, when comparing the transfection, 
cell uptake, and encapsulation efficiency of crosslinked and non-
crosslinked formulations, and in the pre-incubation experiment were 
two-way ANOVA followed by Sidak’s multiple comparison used. For the 
encapsulation efficiency assessed by the RiboGreen assay, Holm−Sidak 
corrected multiple t-tests was used. For the analysis of nanoparticle 
uptake in the Gal8-GFP assay, a two-tailed Student’s t-test was used. For 
the analysis of the in vivo biodistribution, a two-way ANOVA followed 
by Sidak’s multiple comparison was used to compare the fluorescent 
intensity of harvested organs. For the analysis of nanoparticle uptake 
in vivo, one-way ANOVA followed by Tukey’s post hoc test was used 
to compare uptake of different cell types in the lungs. For the analysis 
of siRNA-mediated knockdown in metastatic B16F10-Luc+ tumors, a 
two-way ANOVA followed by Dunnett’s multiple comparison was used to 
examine in vivo delivery efficacy of XbNPs. For the analyses of AST and 
ALT activities and tdTomato expression 15 days after tumor inoculation, 
two-tailed Student’s t-test was used.
Table 1. Antibodies used to assess cellular uptake of nanoparticles in the lungs.
Antigen Color Supplier Clone Dilution Catalog no. Lot no.
CD45 Brilliant Violet 421 Biolegend 30-F11 1:100 103134 B287242
CD31/PECAM Alexa Fluor 700 Biolegend 390 1:100 102443 B303280
CD326/EpCAM APC/Cy7 Biolegend G8.8 1:80 118218 B266989
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